Vaccine Effectiveness Of Bivalent HPV Vaccination Against Genital HPV Of A Catch-Up Campaign And 12 Years Routine Vaccination For Girls-Only: A Biennial Repeated Cross-Sectional Study
Authors:
Preprint
- 19 July 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Background The Netherlands is one of few countries worldwide which has used the bivalent HPV vaccine for girls-only for over a decade. This allows assessment of vaccine effectiveness (VE) against female genital HPV DNA-positivity of this vaccine in an observational post-licensing real-world setting. Additionally, it is unclear whether catch-up vaccination campaigns result in similar VE as routine vaccination. Therefore, type-specific and grouped VE were assessed and compared for women who had been eligible for catch-up vaccination at 13–16 years with those who had been eligible for routine vaccination at 12 years. Methods PASSYON is a Dutch biennial repeated cross-sectional (2011-21) study among sexual health clinic clients aged 16–24 years old. Women provided self-collected vaginal samples, questionnaires on demographics and sexual behaviour were administered, and women self-reported HPV vaccination status. Samples were analysed using a PCR-based assay (SPF10-LiPA25). Type-specific and grouped VE estimates, adjusted with propensity score stratification, were assessed against genital positivity for 14 HPV-types. VE for targeted and non-targeted genotypes were compared between women who had been eligible for the catch-up and those who had been eligible for routine vaccination. Results The study included 4,488 female participants who had been eligible for HPV vaccination and provided genital swabs (1,561 eligible for catch-up, 2,927 for routine vaccination). Very high VE against genital HPV-16 and HPV-18 was observed (resp. 93.5% and 89.5%) and significant cross-protection against six other genotypes (HPV-31/33/35/45/52/58), varying from 18.0% (HPV-52) to 79.6% (HPV-45). VE estimates were comparable between women who had been eligible for the catch-up campaign and those eligible for routine vaccination: VE HPV-16/18: 92.2% (95%CI: 87.9–94.9) vs. 91.8% (95%CI: 86.0-95.2). Conclusions In real-world settings, the VE of bivalent vaccine is high against targeted genotypes, with cross-protection against 6 other genotypes. Catch-up campaigns up to age 16 years can be as effective as routine vaccination at age 12. This may inform countries considering catch-up campaigns when introducing or extending the use of HPV vaccination within their national immunisation programmes.Keywords
All Related Versions
- Version 1, 2024-07-19, Research Square
- Published version: BMC Medicine, 22 (1), 1.
This publication has 38 references indexed in Scilit:
- Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the NetherlandsCancer Medicine, 2023
- Best Practice Guidelines for Propensity Score Methods in Medical Research: Consideration on Theory, Implementation, and Reporting. A ReviewArthroscopy, 2021
- Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in LuxembourgCancer Epidemiology, 2019
- The natural history of human papillomavirus infectionBest Practice & Research Clinical Obstetrics & Gynaecology, 2018
- Epidemiology and burden of HPV-related diseaseBest Practice & Research Clinical Obstetrics & Gynaecology, 2018
- Worldwide burden of cancer attributable to HPV by site, country and HPV typeInternational Journal of Cancer, 2017
- No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitorsJournal of Infection, 2017
- Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort studyVaccine, 2015
- Organization and quality of HPV vaccination programs in EuropeVaccine, 2015
- Propensity Score MethodsAmerican Journal of Ophthalmology, 2010